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Abstract
Background: Bladder cancer patients receiving methotrexate, vinblastine, adriamycin and cisplatin (MVAC)
chemotherapy are co-administered with dexamethasone as an anti-emetic. We examined whether or not
dexamethasone affects the severity and onset day of MVAC-induced severe neutropenia.
Methods: This was a retrospective study of bladder cancer patients treated with MVAC chemotherapy with or
without dexamethasone as an antiemetic at Kanazawa University Hospital during January 2005 - December 2009.
Patients were categorized into three groups; no dexamethasone use (Dex (−)), dexamethasone on day 2 (Dex 1 day),
and dexamethasone on days 2, 3 and 4 (Dex multiday). We evaluated the incidence of grade 3/4 neutropenia and the
day of onset of first severe neutropenic episode during the first course of MVAC chemotherapy. Logistic regression was
used to investigate whether co-administration of dexamethasone was a risk factor for severe neutropenia.
Results: Episodes of grade 3/4 neutropenia occurred in 3 out of 6 (50.0%), 11 out of 12 (91.7%) and 6 out of 6 (100%)
patients in the Dex (−), Dex 1 day, and Dex multiday groups, respectively. The appearance day of first severe
neutropenia in the Dex multiday group (13.2 ± 1.0) was significantly accelerated compared to the Dex (−) group
(17.7 ± 2.1). Univariate logistic regression analysis revealed that dexamethasone is a risk factor for severe neutropenia
(OR 17.0; 95%CI: 1.3–223.1).
Conclusions: Co-administration of dexamethasone for anti-emesis brings forward the first appearance of neutropenia,
and increases the severity of neutropenia, in bladder cancer patients receiving MVAC chemotherapy.
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Background
Cancer chemotherapy with methotrexate, vinblastine,
adriamycin and cisplatin (MVAC) is considered a stand-
ard therapy for urothelial cancer throughout the United
States, Europe, Canada and Japan [1]. The MVAC regi-
men was developed about 30 years ago for transitional
cell carcinoma of urothelium [1]. In a multicenter phase
3 trial, MVAC was shown to provide a survival advan-
tage over cisplatin alone (median survival, 12.5 months
vs 8.2 months, respectively) in patients with metastatic
urothelial carcinoma [2]. However, the toxicity of MVAC
is significant, with about 3–4% incidence of drug-related
deaths, 20–25% incidence of nadir sepsis, and 58%
incidence of grade 3/4 myelosuppression [1, 3]. There-
fore, patients on MVAC therapy require frequent blood
tests to monitor adverse effects.
Dexamethasone is effective for the prevention of eme-
togenic chemotherapy-induced nausea and vomiting
(CINV) [4]. Anti-emetic guidelines such as those of the
Multinational Association of Supportive Care in Cancer,
the European Society of Medical Oncology, the Ameri-
can Society of Clinical Oncology, and the National
Comprehensive Cancer Network recommend dexa-
methasone for prevention of CINV in patients given
anti-tumor agents with low, moderate or high emetic
risk [5, 6]. It was reported that dexamethasone enhances
the anti-emetic effects of 5-HT3 receptor antagonists on
vomiting induced by anti-tumor agents in ferrets [7–9].
Moreover, preclinical studies indicate that corticosteroid
treatment prior to cytotoxic chemotherapy markedly
reduced liver and bone marrow toxicity [10–13].
However, the safety of corticosteroid co-administration
in this context has not been established.
In Kanazawa University Hospital Department of
Urology, dexamethasone was initially not used for anti-
emesis, because of potential side-effects such as
increased susceptibility to infection, diabetes and osteo-
porosis. But, since vomiting and nausea in urothelial
patients on MVAC therapy could not be controlled with-
out dexamethasone, co-administration of dexametha-
sone with MVAC therapy was started in 2006. However,
we noted an increase in the incidence of severe neutro-
penia and an earlier onset of first severe neutropenia in
patients after the introduction of dexamethasone.
We found that relatively little is known about the side
effects of dexamethasone in patients receiving emeto-
genic cancer chemotherapy [14], and in particular, it is
not known whether co-administration of dexamethasone
with cancer chemotherapy influences the severity or on-
set day of neutropenia.
Therefore, the aim of this study was to examine
whether dexamethasone used as an anti-emetic affects
the severity and/or frequency of neutropenia in bladder
cancer patients receiving MVAC chemotherapy.
Methods
Data sources and cohort
This retrospective cohort study was conducted via a
search of the computerized medical records at Kanazawa
University Hospital. The files contain details of hospital
procedures as well as patient demographics, laboratory
data, drugs administered, doses, and date of administra-
tion. The study cohort was defined as all patients with
urothelial cancer who received the first course of MVAC
therapy at Kanazawa University Hospital from January
1st, 2005, to December 31th, 2009. Exclusion criteria
included patients receiving an aprepitant, or corticoste-
roids other than dexamethasone.
The procedure of MVAC chemotherapy is as follows.
A dose of 30 mg/m2 methotrexate is administered by
intravenous (IV) infusion on days 1, 15 and 22. A dose
of 3.0 mg/m2 vinblastine is administered by IV infusion
on days 2, 15 and 22. Doses of 30 mg/m2 adriamycin
and 70 mg/m2 cisplatin are administered by IV infusion
day 2. The cycle is repeated every 28 days. Urothelial
patients on MVAC therapy were classified according to
the duration of dexamethasone co-administration. The
survey covered six patients who received no dexametha-
sone (Dex (−)), twelve patients who received dexametha-
sone (8 mg) once on day 2 of MVAC (Dex 1 day), and
six patients who received multiple administrations of
dexamethasone (day 2, 8 mg; day 3, 2 mg; day 4, 2 mg)
(Dex multiday). Granulocyte-colony stimulating factor
(G-CSF) was used only when the neutrophil count fell
below 1000 cells/μL neutrophils, in accordance with
Japanese health insurance treatment recommendations
during this study period. 5-HT3 antagonist (granisetron
hydrochloride 3 mg or ondansetron hydrochloride hy-
drate 4 mg) was used 2 times on day 2 for all patients as
another anti-emesis drug. Ticlopidine hydrochloride,
aspirin, pravastatin, rosuvastatin calcium, bezafibrate, ni-
fedipine, benidipine hydrochloride, and allopurinol, used
as concomitant medicines, have been reported to cause
leucopenia as a side effect. Other concomitant medica-
tions are described in Table 1.
Laboratory values were monitored at the physician’s
discretion, but blood counts were consistently taken
around day 15 (when methotrexate and vinblastine were
administered). There was no significant difference of
blood test measurement times among the Dex (−), Dex
1 day and Dex multiday groups in the first course of
MVAC therapy (11.3 ± 2.2, 11.4 ± 2.5, and 10.0 ± 2.3,
respectively).
The effects of baseline laboratory data (neutrophil
counts <2000 cells/μL, total bilirubin >0.5 mg/dL, aspar-
tate aminotransferase (AST) >27 U/L, creatinine clear-
ance <60 mL/min), age of the patient (>65 y), body mass
index (BMI) <23 kg/m2 and male sex) were evaluated, for
comparison with a retrospective study on neutropenia in
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lung cancer patients [15]. BMI was calculated as weight
(kg)/height2 (m2).
Nadir neutrophil counts after MVAC chemotherapy
were recorded as the major outcome. We defined severe
neutropenia as grade 3 or 4 neutropenia according to
the Common Terminology Criteria for Adverse Events,
version 4.0.
This study was carried out in compliance with the
requirements of the Ethics Committee at Kanazawa
University (protocol No.1008). All analyses were
performed using anonymized data.
Statistical analysis
Descriptive statistics were used for patients’ baseline
clinical characteristics and the presence of drug adminis-
tration. Continuous data are expressed as median with
interquartile range. Categorical data are presented as
frequency (percentage). Univariate logistic regression
analyses were performed to identify risk factors for
severe neutropenia. A p value less than 0.05 was consid-
ered significant.
All statistical analysis was performed using the statis-
tical software package SPSS version 19.0J (SPSS Japan




The demographic characteristics of the patients are sum-
marized in Table 1. There were no significant differences
in age, sex, performance status, body surface area, BMI,
creatinine clearance, total bilirubin, AST and concomi-
tant medications among the Dex (−), Dex 1 day and Dex
multiday groups (Table 1).
Severity of severe neutropenia
The incidence of severe neutropenia increased with in-
creasing number of days of dexamethasone, and the Dex
multiday group showed a significantly greater incidence
of grade 4 neutropenia compared to the Dex (−) group
(Table 2).
Day of onset of first severe neutropenia
The day of onset of first severe neutropenia was defined
as the first detection day of neutrophil count <1000
cells/μL after MVAC chemotherapy (started on day 1).
Dexamethasone significantly accelerated the day of onset
of first severe neutropenia compared to the Dex (−)
group, and the Dex multiday group showed the earliest
onset (Table 3).
Usage of G-CSF
Dexamethasone treatment tended to be associated with
increased incidence of G-CSF usage compared to the
Dex (−) group (Table 4). In particular, in the Dex multi-
day group, all patients required G-CSF. Also, the day of
Table 1 Patient demographics
Dex (−) (n = 6) Dex 1 day (n = 12) Dex multiday (n = 6)
Age (year) 67.3 (58–73) 67.0 (57–79) 69.5 (57–76)
Sex (male/female) 5/1 12/0 3/3
PS (0/1/2) 5/1/0 10/1/1 6/0/0
Body surface area (m2) 1.8 (1.5–2.0) 1.7 (1.5–1.8) 1.6 (1.4–1.8)
BMI (kg/m2) 22.9 (19.8–28.1) 21.2 (15.9–27.5) 24.7 (19.3–30.0)
Creatinine clearance (mL/min) 94.5 (62.3–125.1) 99.8 (55.6–143.7) 98.5 (65.9–143.8)
Total bilirubin (mg/dL) 0.53 (0.4–0.8) 0.63 (0.3–1.4) 0.72 (0.5–1.3)
AST (IU/L) 24.7 (12–31) 22.0 (10–32) 18.3 (15–21)
Concomitant medications
Oral 5HT3 receptor antagonists (%) 83.3 33.3 100
Dopamine antagonists (%) 50 33.3 50
Drugs reported leucopenia (%) 50 41.7 33.3
Purgative medicine (%) 50 50 50
Data are mean values (range in parentheses)
PS performance status, AST aspartate transaminase, 5HT serotonin, BMI body mass index
Table 2 Severity of neutropenia in patients on the first course
of MVAC chemotherapy
Neutropenia Dex (−) (n = 6) Dex 1 day (n = 12) Dex multiday (n = 6)
G3 (%) 50.0 41.7 0
P value 1.0 0.18
G4 (%) 0 50.0 100.0
P value 0.054 0.002
G3/4 (%) 50.0 91.7 100.0
P value 0.08 0.18
P values are for G3, G4 and G3/4 neutropenia with Dex (1 day or multiday)
versus DEX (−), as determined by Fisher’s exact test
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onset of the first G-CSF use was significantly accelerated
compared to the Dex (−) group.
Risk factors for severe neutropenia
Univariate logistic regression analysis showed that dexa-
methasone use was associated with severe neutropenia,
with odds ratios of 17.0 (95% CI 1.3 to 223.1) (Table 5).
Neutrophil counts <2000 cells/μL and aspartate amino-
transferase (AST) >27 U/L could not be analyzed because
appropriate patients were not present in all groups. Other
factors showed no association with severe neutropenia.
Discussion
This is the first report to suggest that co-administration
of dexamethasone for anti-emesis induces severe neutro-
penia in patients receiving MVAC chemotherapy. The
severity of MVAC-induced neutropenia was increased
dose-dependently by dexamethasone, and the first onset
of severe neutropenia was brought forward. Because
severe neutropenia is an indication for reduced dose of
anti-cancer agents, co-administration of dexamethasone
appears likely to diminish the effectiveness of MVAC
therapy. In particular, first severe neutropenia appeared
around day 13 in the DEX multiday group, so that these
patients would not be eligible to receive administration
of methotrexate and vinblastine on day 15 of MVAC
chemotherapy.
Current clinical practice guidelines recommend the
use of G-CSF for prevention of febrile neutropenia [16],
but during this clinical study period, G-CSF was given
only when the neutrophil count fell below 1000 cells/μL,
in accordance with Japanese health insurance treatment
recommendations at the time. Thus, we considered that
G-CSF would have had no effect on the incidence of
severe neutropenia during MVAC therapy with dexa-
methasone. Usage of G-CSF tended to be greater in
groups that received Dex treatment.
Ageing, poor performance status, advanced disease,
certain comorbidities, low baseline values of blood cell
counts, low body surface area/BMI, treatment with mye-
losuppressive chemotherapies, and specific genetic poly-
morphisms are reported to correlate with the risk of
developing febrile neutropenia [17]. Although the
present study did not include patients with advanced
disease, certain comorbidities and specific genetic poly-
morphisms, univariate logistic regression analysis indi-
cated that ageing, poor performance status, and BMI
were not related to the incidence of severe neutropenia,
and dexamethasone was the only risk factor identified
for onset of severe neutropenia. The main reason for this
difference may be the difference of chemotherapy regimens.
MVAC chemotherapy frequently induces severe neutro-
penia compared to other chemotherapies, and therefore pa-
tients require careful monitoring.
Some reports have indicated that pretreatment with
corticosteroids can induce tolerance to anti-cancer
agents in vitro, or alter the pharmacokinetics of anti-
cancer agents [10, 11]. Corticosteroid was also reported
to confer resistance to cisplatin-induced apoptosis in
human cervical and lung carcinoma cells [18]. However,
our patients received dexamethasone simultaneously
with MVAC, and so these mechanisms may not be
relevant here.
Possible mechanisms through which dexamethasone
might accelerate severe neutropenia include induction of
Table 3 Day of onset of first severe neutropenia in patients on







Day of onset of severe
neutropenia
17.7 ± 2.1 15.1 ± 2.1 13.2 ± 1.0
P value 0.113 0.008
Data are mean ± SD. P values are for day of onset of severe neutropenia with
Dex (1 day or multiday) versus Dex (−), as determined by ANOVA with post
hoc Tukey’s test







G-CSF use (%) 50 75 100
P value 0.34 0.18
Day of Onset of first G-CSF use 18.0 ± 2.0 15.1 ± 2.7 13.7 ± 1.5
P value 0.17 0.04
P values are for G-CSF use with Dex 1 day and multiday versus Dex (−), as
determined by Fisher’s exact test
Onset day of G-CSF first use data are mean ± SD. P values are for onset day of
G-CSF use with Dex (1 day or multiday) versus Dex (−), as determined by
ANOVA with post hoc Tukey’s test
Table 5 Risk factors associated with Grade 3/4 neutropenia
among 24 patients undergoing MVAC therapy at the first course,
univariate logistic regression analysis





Dexamethasone (+) : 94.4 17.0 (1.3–223.1) 0.03
(−) : 50.0
Age (>65 y) (+) : 88.2 3.0 (0.33–27.2) 0.33
(−) : 71.4
Female Female : 75.0 0.5 (0.04–7.0) 0.63
Man : 85.0
PS (>0) (+) : 66.7 0.3 (0.02–4.9) 0.42
(−) : 85.7
Total bilirubin (>0.5 mg/dL) (+) : 90.9 3.0 (0.3–34.0) 0.38
(−) : 76.9
BMI (<23 kg/m2) (+) : 84.6 1.2 (0.1–10.5) 0.86
(−) : 81.8
OR odds ratio, PS performance status, BMI body mass index, CI
confidence interval
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granulocytosis and rapid progenitor cycling, which could
heighten bone marrow chemo-sensitivity. This could
occur through various mechanisms, such as enhanced re-
lease of polymorphonuclear leukocytes from bone mar-
row, delayed apotosis, and entry of polymorphonuclear
leukocytes into inflamed tissues [19]. This idea is sup-
ported by evidence that patients receiving G-CSF concur-
rently with chemotherapy have more profound
neutropenia or depressed neutrophil recovery as com-
pared with historical controls or patients not treated with
G-CSF and chemotherapy simultaneously [20, 21]. An-
other possible mechanism is drug-drug interaction be-
tween dexamethasone and MVAC components. Increased
hepatotoxicity of methotrexate has been reported during
dexamethasone therapy in humans [22] and rats [23]. This
may be due to an increase of drug concentration in liver
arising from reduced biliary elimination of the drug in the
presence of dexamethasone [24]. However, it is not yet
known whether or not the pharmacokinetics of vinblast-
ine, cisplatin and adriamycin are affected by co-
administration with dexamethasone in human and
animals.
Our study has several limitations. 1) Since the data
were obtained from clinical records, blood counts were
not monitored as frequently as would be needed for ac-
curate determination of nadir neutrophils, and the tim-
ing of blood counts was not the same for all subjects. 2)
We could not determine the possible contribution to fe-
brile neutropenia of other risk factors, including genetic
polymorphisms, advanced disease, and certain comor-
bidities, although we did find that concomitant usage of
other drugs had no apparent effect on neutropenia. Also,
3) our study is a single-center retrospective cohort study
with relatively few subjects, so it is difficult to eliminate
various possible biases and confounding factors. We
could not add more patients to this clinical study, since
dexamethasone should administered to patients treated
with highly emetic chemotherapy according to current
guidelines. Further research will be needed to establish
the optimum dose and schedule of dexamethasone in in-
dividual patients, and to clarify the mechanisms through
which dexamethasone affects hemocytes, including
blood stem cells.
Conclusions
We present the first evidence suggesting that co-
administration of dexamethasone for anti-emesis in-
creases the severity of neutropenia and brings forward
the onset day of neutropenia in bladder cancer patients
receiving MVAC chemotherapy.
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